evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

76 questions · 77 findings · 27 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 22 · 28.6%GRADE not reported 5 · 6.5%Very low 25 · 32.5%Low 18 · 23.4%Moderate 6 · 7.8%High 1 · 1.3%

Summary of Findings Table ‐ Electrocoagulation in combination with allopurinol or with dimethyl sulphoxide vs control (vehicle solution of allopurinol by mouth)

All‐cause mortality at last · people with liver metastases

Summary of Findings Table ‐ Electrocoagulation in combination with… may leads to lower all‐cause mortality at last compared with control (vehicle solution of allopurinol by mouth) (low certainty).

1 finding from 1 review

Dopamine‐milrinone vs dopamine‐dobutamine

All‐cause short‐term mortality: at intensive care unit · adults with cardiogenic shock

It is very uncertain whether dopamine‐milrinone changes all‐cause short‐term mortality: at intensive care unit compared with dopamine‐dobutamine (very low certainty).

1 finding from 1 review

Glycopeptide (vancomycin or teicoplanin) plus aminoglycoside (gentamicin) vs beta‐lactam (cloxacillin) plus aminoglycoside (gentamicin)

All‐cause mortality during hospital stay and all‐cause mortality at 1 year · people with endocarditis due to Staphylococcus aureus in drug abusers

The review found no eligible studies for this question.

1 finding from 1 review

Inositol supplementation IV initially followed by enteral administration (repeat doses of 80 mg/kg/day) in preterm infants born at less than 30 weeks' PMA vs placebo

All‐cause mortality (outcome collected through first event: death, hospital discharge, hospital transfer, or 120 days after birth) · preterm infants with or at risk of respiratory distress syndrome

Inositol supplementation IV initially followed by enteral… showed no clear difference in all‐cause mortality (outcome collected through first event: death,… compared with placebo (moderate certainty).

1 finding from 1 review

FIBRINOGEN: Therapeutic trials: intervention vs inactive control

All‐cause mortality Up to 28 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia

FIBRINOGEN: Therapeutic trials: intervention showed no clear difference in all‐cause mortality Up to 46 days post‐operatively compared with inactive Control (high certainty).

1 finding from 1 review

FIBRINOGEN: Therapeutic trials: intervention vs haemostatically active control

All‐cause mortality Up to 28 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
2 findings from 1 review

FIBRINOGEN: Therapeutic trials: intervention vs inactive control

All‐cause mortality Up to 28 days following admission · the prevention and treatment of bleeding in patients without haemophilia

FIBRINOGEN: Therapeutic trials: intervention showed no clear difference in all‐cause mortality Up to 28 days following admission compared with inactive Control (moderate certainty).

1 finding from 1 review

FIBRINOGEN: Therapeutic trials: intervention vs inactive control

All‐cause mortality In‐hospital mortality up to 30 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia

FIBRINOGEN: Therapeutic trials: intervention showed no clear difference in all‐cause mortality In‐hospital mortality up to 30 days… compared with inactive Control (low certainty).

1 finding from 1 review